Scholar Rock SRRK Business Segments
| FY'25 | FY'24 | ||
|---|---|---|---|
| Research And Development Expense by Product | |||
| Apitegromab | $89.8M+14.7% | $78.29M— | |
| Early Research | $6.68M+119% | $3.05M-31.8% | |
| RD Expense Srk181 | $2.41M-75.8% | $9.96M— | |
| RD Expense Srk439 | $8.97M-22.9% | $11.64M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Scholar Rock break its business down?
- Scholar Rock (SRRK) reports research and development expense by product across 4 parts — Apitegromab, Early Research, RD Expense Srk181 and RD Expense Srk439. Each is extracted from the segment footnotes and tracked over time.
- Where does Scholar Rock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Scholar Rock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.